GSTP1 and Stroke: Interestingly, compared to 28 molecules classically described in stroke research, GST-π emerged as the best biomarker with promising clinical performances associated with an early elevation within the first 3 h after stroke onset and a potential interest for discriminating eligible vs. ineligible patients for thrombolytic therapy.